Back to Newsroom

Capricor Therapeutics Appoints Thomas Copmann, Ph.D. as Vice President of Regulatory Affairs and Drug Development

LOS ANGELES, Feb. 27, 2015 (GLOBE NEWSWIRE) — Capricor Therapeutics, Inc.(OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that Thomas Copmann, Ph.D., has been appointed to the newly created position of Vice President of Regulatory Affairs and Drug Development. In this role, Dr. Copmann will lead the company’s regulatory initiatives and strategy, ensure appropriate regulatory compliance in the conduct of all Capricor development programs and manage reporting to the FDA and health authorities.

Click here to read more